Statement of Need
Urology Practitioners need a thorough knowledge of the most recent developments and techniques as well as established guidelines in urology to ensure the highest standards of patient care and safety.
Learning Objectives
At the conclusion of the 2024 Annual Meeting, participants should be able to:
- Describe recent developments in the medical and surgical management of urology patients.
- Identify new technologies for the treatment of urologic conditions.
- Integrate the latest guidelines on the management of urological diseases into their practice.
- Incorporate evidence based research and literature into the shared decision making process.
Method of Participation
Learners will participate by attending the in-person session(s), logging into the live virtual session(s) or logging into the on-demand (enduring) activity(ies) beginning May 2, 2024 through August 31, 2024. After completing selected sessions/activities, learners will complete the credit claim attestation and activity evaluation.
Accreditation Statement
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American Urological Association designates this other activity (live and enduring materials) activity for a maximum of 476 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence-Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy
All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The AUA must determine if the individual's relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships for AUA2024 are available for review by clicking the button below.
Mitigation of Identified Conflict of Interest
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
Off-label or Unapproved Use of Drugs or Devices
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.